PCSK9 Inhibitors: A New Era in Lipid-Lowering Treatment?

被引：13
|
作者：
Cainzos-Achirica, Miguel [1 ]
Martin, Seth S. [1 ]
Cornell, John E.
Murow, Cynthia D.
Guallar, Eliseo
机构：
[1] Johns Hopkins Med Inst, Baltimore, MD 21205 USA
来源：
ANNALS OF INTERNAL MEDICINE | 2015年 / 163卷 / 01期
关键词：
HYPERCHOLESTEROLEMIA; LDL;
D O I：
10.7326/M15-0920
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：64 / 65
页数：2
相关论文
共 50 条
  • [31] Improvement of retinal microvascular function after initiation of lipid-lowering therapy with PCSK9 inhibitors - an observational study
    Naegele, M.
    Raemy, Y.
    Barthelmes, J.
    Kreysing, L.
    Haider, T.
    Ruschitzka, F.
    Flammer, A. J.
    Sudano, I.
    EUROPEAN HEART JOURNAL, 2021, 42 : 3363 - 3363
  • [32] Limitations of cholesterol lowering with PCSK9 inhibitors
    Thompson, Gilbert
    LANCET DIABETES & ENDOCRINOLOGY, 2017, 5 (04): : 241 - 243
  • [33] Lower is better: ezetimibe and PCSK9 inhibition join the mainstream of lipid-lowering therapy
    Wojcik, Cezary
    REVIEWS IN HEALTH CARE, 2016, 7 (01) : 17 - 25
  • [34] Lipid-lowering PCSK9 sequence variants protect against coronary heart disease
    Nature Clinical Practice Cardiovascular Medicine, 2006, 3 (7): : 350 - 350
  • [35] Potential barriers in lipid-lowering treatment with PCSK9 inhibitors from a healthsystem perspective. Comparative evidence from ten countries
    Apostolou, E. A.
    Main, C. A.
    Miracolo, A.
    Papadakis, K.
    Paparouni, K.
    Kanavos, P. G.
    EUROPEAN HEART JOURNAL, 2022, 43 : 2348 - 2348
  • [36] Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
    Ye-Xuan Cao
    Jing-Lu Jin
    Di Sun
    Hui-Hui Liu
    Yuan-Lin Guo
    Na-Qiong Wu
    Rui-Xia Xu
    Cheng-Gang Zhu
    Qian Dong
    Jing Sun
    Jian-Jun Li
    Journal of Translational Medicine, 17
  • [37] Circulating PCSK9 and cardiovascular events in FH patients with standard lipid-lowering therapy
    Cao, Ye-Xuan
    Jin, Jing-Lu
    Sun, Di
    Liu, Hui-Hui
    Guo, Yuan-Lin
    Wu, Na-Qiong
    Xu, Rui-Xia
    Zhu, Cheng-Gang
    Dong, Qian
    Sun, Jing
    Li, Jian-Jun
    JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (01)
  • [38] PCSK9 INHIBITORS: THE BREAKTHROUGH LIPID-LOWERING TREATMENT AT REAL-LIFE SETTING. A 2-YEAR REGIONAL LIPID CLINIC EXPERIENCE
    Anastasiou, G.
    Liamis, G.
    Milionis, H.
    Elisaf, M.
    Christopoulou, E.
    Dimitriou, T.
    Liberopoulos, E.
    ATHEROSCLEROSIS, 2020, 315 : E257 - E257
  • [39] PCSK9 INHIBITORS: THE BREAKTHROUGH LIPID-LOWERING TREATMENT AT REAL-LIFE SETTING. A 3-YEAR REGIONAL LIPID CLINIC EXPERIENCE
    Anastasiou, G.
    Liamis, G.
    Milionis, H.
    Elisaf, M.
    Christopoulou, E.
    Dimitriou, T.
    Liberopoulos, E. N.
    ATHEROSCLEROSIS, 2021, 331 : E134 - E134
  • [40] Effect of adding PCSK9 inhibitors to lipid-lowering interventions on arterial stiffness: A systematic review and meta-analysis
    Cavero-Redondo, I.
    Moreno-Herraiz, N.
    Del Saz-Lara, A.
    Otero-Luis, I.
    Recio-Rodriguez, J. I.
    Saz-Lara, A.
    EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2024, 54 (10)
12345